| 新股发行及今日交易提示 | 2025/5/16 | 星期五 | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 2025/5/16 | 新股上市 | 证券代码 | 证券简称 | 发行价格 | | | | | 301636 | 泽润新能 | 33.06 | 688755 | 汉邦科技 | 22.77 | | | | 2025/5/16 | 内地市场权益提示 | 类别 | 证券代码 | 证券简称 | 权益日期 | 最新公告链接 | | | https://www.cninfo.com.cn/new/disclosure/detail?stockCode=600777&announcementId=122353 | 要约收购 | 600777 | ST新潮 | 要约申报期：2025年4月23日至2025年5月22日 | 6545&orgId=gssh0600777&announcementTime=2025 | -05-14 | | | http://www.cninfo.com.cn/new/disclosure/detail?sto ...

Company Overview - Jiangsu Hanbang Technology Co., Ltd. was established in 1998 and currently employs over 650 people. It is recognized as a national high-tech enterprise and a "little giant" enterprise specializing in technology [5][8]. - The company focuses on providing professional separation and purification equipment, consumables, application technology services, and related technical solutions for the pharmaceutical and life sciences sectors [7]. Market Performance - On May 16, 2023, Hanbang Technology successfully listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board, with a stock price of 22.77 yuan per share [3]. - On its first trading day, the stock surged by 115.20%, reaching a price of 49 yuan, resulting in a market capitalization of 4.312 billion yuan. The stock price later exceeded 50 yuan, with a rise of over 120% [4]. Innovation and Recognition - The company has a strong commitment to independent innovation, holding a total of 51 authorized invention patents, including 38 domestic and 13 overseas patents [8]. - Hanbang Technology has led or participated in 15 provincial-level or higher scientific research or industrialization projects, including six national-level projects [8]. Industry Position - Hanbang Technology holds a leading market share in the domestic chromatography separation and purification equipment market and aims to become a mainstream provider of overall solutions for global pharmaceutical companies [8]. - The company serves over 2,000 clients, including well-known domestic pharmaceutical enterprises such as Heng Rui Medicine, Zhengda Tianqing, and international clients from countries like Germany, the UK, India, South Korea, and Norway [8].

Group 1: Automotive Industry - The automotive supply chain sector in the A-share market experienced a surge, with multiple stocks hitting the daily limit up [2][4] - A new mandatory national standard for light vehicle automatic emergency braking systems (AEBS) has been drafted and is now open for public consultation, set to replace the existing standard by June 30, 2025 [3][4] - The new standard expands the requirement for AEBS to include not only passenger cars (M1 category) but also light commercial vehicles (N1 category), indicating a significant market shift [4][6] Group 2: Robotics Sector - The robotics concept stocks saw a notable increase, with companies like Greebo and Haon Electric hitting the daily limit up, and several others rising over 10% [9][10] - China Unicom announced a partnership with Huawei to launch a home robot product, indicating a growing interest in domestic robotics [10] - The domestic robotics industry is expected to enter a mass production phase by 2025, driven by advancements in data accumulation and hardware cost reductions [10] Group 3: Market Performance - The overall A-share market showed low volatility, with the Shanghai Composite Index down 0.52% and the Shenzhen Component Index slightly up by 0.08% [2] - In the Hong Kong market, NetEase saw a significant increase, with its stock price rising over 16% during the session [17][19]

Group 1: A-Share Market Overview - The A-share market experienced overall low-level fluctuations in the morning, with the automotive industry chain sector leading the gains, becoming one of the important highlights of the market [1][4] - The Shanghai Composite Index fell by 0.52%, while the Shenzhen Component Index slightly increased by 0.08%, and the ChiNext Index rose by 0.16% [4] - A significant number of stocks in the automotive industry chain hit the daily limit, including companies like Haoen Electric and Tianqimo [4][5] Group 2: Automotive Industry Standards - A new mandatory national standard for light vehicle automatic emergency braking systems (AEBS) has been drafted and is now in the public consultation phase, set to replace the current standard GB/T 39901-2021 [5][6] - This new standard expands the scope to include N1 class light commercial vehicles, requiring all passenger cars (M1 class) and light commercial vehicles (N1 class) to be equipped with AEBS [6][8] - The implementation of this mandatory standard indicates a countdown for large-scale pre-installation of AEBS in the Chinese automotive market [8] Group 3: Robotics Sector - The robotics concept saw a rise, with stocks like Greebo and Haoen Electric hitting the daily limit, and several others increasing by over 10% [12] - China Unicom announced the launch of a home robot product in collaboration with Huawei, indicating a growing interest in the robotics sector [13] - The domestic robotics industry is expected to enter a mass production phase by 2025, driven by data accumulation and hardware cost reductions [13] Group 4: New Stock Listings - Two new stocks were listed in the A-share market, both experiencing significant price increases, with Hanbang Technology rising over 140% [18] - Hanbang Technology focuses on chromatography technology and provides solutions for the pharmaceutical and life sciences sectors [18][19] - Another new stock, Zerun New Energy, saw a price increase of over 120%, specializing in photovoltaic component junction box solutions [20] Group 5: Hong Kong Market Overview - The Hong Kong market also experienced low-level fluctuations, with NetEase-S seeing a significant increase, reaching a peak of over 16% [21][23] - NetEase reported a net income of RMB 28.8 billion for Q1 2025, a year-on-year increase of 7.4%, with its gaming and related services net income rising by 12.1% [25][26]

Company Overview - N Hanbang has been listed today with an opening price of 49.00 yuan, representing an increase of 115.20% from its issue price [2] - The company focuses on chromatography technology, integrating research and development, production, and sales, primarily serving the pharmaceutical and life sciences sectors with specialized separation and purification equipment, consumables, application technology services, and related technical solutions [2] Financial Highlights - The total number of shares issued by the company is 22 million, with an online issuance of 7.04 million shares at an issue price of 22.77 yuan per share [2] - The issue price corresponds to a price-to-earnings (P/E) ratio of 26.35, compared to the industry average P/E ratio of 28.04 [2] - The total funds raised from the initial public offering (IPO) amount to 501 million yuan, which will be used for working capital, the construction of a chromatography separation equipment R&D center, and the production projects for laboratory chromatography separation and purification instruments [2] Recent IPO Performance - N Hanbang's first-day performance is notable, with a significant increase of 115.20% [2] - Other recent IPOs on the same day include N Zairun, which saw a rise of 98.12%, and Tian Gong Co., which experienced a dramatic increase of 458.63% [3]

Core Viewpoint - Hanbang Technology has successfully transitioned from a chromatography consumables agent to a leading domestic manufacturer of preparative chromatography equipment, becoming the first stock of chromatography equipment on the Sci-Tech Innovation Board [3][4]. Company Development - Established in 1998, Hanbang Technology initially focused on the agency sales of chromatography consumables, facing market saturation by 2006, which prompted a shift towards independent research and development [4]. - The company launched its first dynamic axial compression column in 2005, and by 2012, revenue from self-developed products surpassed that from agency sales [4][5]. - By 2024, Hanbang Technology was recognized as a "little giant" enterprise by the Ministry of Industry and Information Technology, ranking first in the domestic production-grade small molecule liquid chromatography system market [5]. Talent and R&D - Since 2010, Hanbang Technology has focused on attracting and retaining R&D talent, forming a technical team of 141 members by 2024, including 5 core technical personnel [5]. - The company implements various incentive measures, such as salary bonuses and stock options, to stabilize and develop its core technical team [5]. Market Position and Clientele - Hanbang Technology primarily serves the pharmaceutical industry, with notable clients including domestic giants like Heng Rui Medicine and international pharmaceutical equipment integrators [6][7]. - The company emphasizes the importance of high-purity separation and purification technologies, which are increasingly demanded due to stringent regulatory requirements [7]. Business Model and Solutions - Hanbang Technology adopts a dual approach of product development and customized turnkey services, offering solutions for both small and large molecule drug separation and purification [7]. - The company provides tailored solutions based on client sample characteristics, optimizing chromatography filler performance to reduce production costs [7]. Financial Performance - The company's revenue has shown consistent growth, with figures of 482 million yuan, 619 million yuan, and 691 million yuan from 2022 to 2024, respectively [8]. - Net profit attributable to the parent company has also increased, reaching approximately 79.34 million yuan in 2024 [8]. Future Outlook - Hanbang Technology anticipates continued growth in the domestic liquid chromatography market, with the laboratory liquid chromatography market projected to reach 3.6 billion yuan by 2026 [8]. - The company plans to raise funds through an IPO to enhance production capacity and R&D capabilities, with specific projects aimed at increasing production of chromatography equipment and laboratory instruments [8][9]. - Future technical focuses include optimizing chromatography system pressure resistance, fluid distribution, sealing, and homogenization technologies, as well as developing higher selectivity chromatography materials [9].

江苏汉邦科技股份有限公司 首次公开发行股票科创板 上市公告书提示性公告 保荐人（主承销商）：中信证券股份有限公司 扫描二维码查阅公告全文 本公司及全体董事、监事、高级管理人员保证信息披露的内容真实、准确、 完整、及时，没有虚假记载、误导性陈述或重大遗漏。 经上海证券交易所审核同意，江苏汉邦科技股份有限公司（以下简称"汉邦 科技"、"公司"、"本公司"或"发行人"）发行的人民币普通股股票将于 2025 年 5 月 16 日在上海证券交易所科创板上市，上市公告书全文和首次公开发行股 票的招股说明书在上海证券交易所网站（http://www.sse.com.cn/）和符合中国证 监 会 规 定 条 件 网 站 （ 中 国 证 券 网 ， http://www.cnstock.com ； 中 证 网 ， http://www.cs.com.cn ； 证 券 时 报 网 ， http://www.stcn.com ； 证 券 日 报 网 ， http://www.zqrb.cn）披露，并置备于发行人、上交所、本次发行保荐人（主承销 商）中信证券股份有限公司的住所，供公众查阅。 一、上市概况 （一）股票简称：汉邦科技 （ ...

股票简称：汉邦科技 股票代码：688755 江苏汉邦科技股份有限公司 Jiangsu Hanbon Science and Technology Co., Ltd. （淮安经济技术开发区新竹路 10 号；淮安经济技术开发区集贤路 1-9 号） 首次公开发行股票科创板上市公告书 保荐人（主承销商） 广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座 二〇二五年五月十五日 江苏汉邦科技股份有限公司 上市公告书 特别提示 江苏汉邦科技股份有限公司（以下简称"汉邦科技"、"本公司"、"发 行人"、"公司"）股票将于 2025 年 5 月 16 日在上海证券交易所科创板上市。 本公司提醒投资者应充分了解股票市场风险及本公司披露的风险因素，在 新股上市初期切忌盲目跟风"炒新"，应当审慎决策、理性投资。 1 江苏汉邦科技股份有限公司 上市公告书 第一节 重要声明与提示 一、重要声明与提示 本公司及全体董事、监事、高级管理人员保证上市公告书所披露信息的真 实、准确、完整，承诺上市公告书不存在虚假记载、误导性陈述或重大遗漏， 并依法承担法律责任。 上海证券交易所、有关政府机关对本公司股票上市及有关事项的意见，均 不表明 ...

江苏汉邦 日限公 (草案) 2023年 4月 4-2-1 t and the | 第一章 | 总 则 | | --- | --- | | 第二章 | 经营宗旨和范围 | | 第三章 | 股 价 | | 第四章 | 股东和股东大会 . | | 第五章 | 董事会 ……………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………23 | | 第六章 | 总经理及其他高级管理人员 . | | 第七章 | 业事公 ………………………………………………………………………………………………………………35 | | 第八章 | 财务会计制度、利润分配和审计 . | | 第九章 | 通知和公告 | | 第十章 | 合并、分立、增资、减资、解散和清算 | | | 第十一章 修改章程. | | | 第十二章 附 则 ……………………………………………………………………………………………………………………………………………………………………………………… ...

Core Viewpoint - The new share issuance results of Weigao Blood Purification indicate a strong interest from online investors, with a total subscription amount of 707.77 million yuan and a low abandonment rate of 0.544% [1][2][3]. Summary by Category Subscription Details - Online investors subscribed for 26,708,400 shares, amounting to 707.77 million yuan, while offline investors subscribed for 12,512,100 shares, totaling 331.57 million yuan [2][3]. - The total number of shares issued was 41,139,400, with an issuance price of 26.5 yuan per share [3]. Abandonment Rates - The online abandonment quantity was 146,100 shares, with an abandonment amount of 3.87 million yuan, while offline abandonment was minimal at 695 shares, amounting to 18,400 yuan [1][2]. - The overall abandonment rate for online subscriptions was 0.544%, with the abandonment amount being 387.16 thousand yuan [1][3]. Market Context - In the context of recent new share issuances, Weigao Blood Purification ranked among the top in terms of abandonment quantity and rate, with notable competitors including Tian You Wei and Jiang Shun Technology [3]. - The online issuance final winning rate was 0.03215719%, and the strategic allocation was 1,772,100 shares [3].